SA Pro author Stephen Simpson's bullish take on Sanofi (SNY) touches on the blockbuster...

|About: Sanofi (SNY)|By:, SA News Editor

SA Pro author Stephen Simpson's bullish take on Sanofi (SNY) touches on the blockbuster potential of the company's MS drug, Lemtrada. A commenter points out Contingent Value Rights on Lemtrada allow investors a pure-play bet on the drug's success. The possible undervaluation of the CVR is covered in an interesting article by SA Pro author Chris DeMuth (along with great comment thread).